Ethics and social acceptability of a proposed clinical trial using maternal gene therapy to treat severe early-onset fetal growth restriction by Sheppard, M et al.
 Ethics of gene therapy, Version 1.0, 14/12/2015  Page 1 
 
Full Title: Ethics and social acceptability of a proposed clinical trial using maternal gene therapy to treat 1 
severe early onset fetal growth restriction  2 
Short Title: Ethics of gene therapy 3 
Authors: Dr Maria Sheppard PhD
1
* 4 
Dr Rebecca N Spencer MRCOG
2
* 5 





  Dr Anna L David PhD MRCOG
2
 8 
*Joint first authors 9 
Institutions: 
1
School of Law, Queen Mary University of London, London, E1 4NS, UK 
2
Institute for 10 
Women’s Health, University College London, 86-96 Chenies Mews, London, WC1E 6HX  11 
3
EVERREST Consortium: Dr Gareth Ambler (UK), Dr Jana Brodszki (Sweden), Dr David Campbell (Magnus 12 
Life Science, UK), Dr Anke Diemert (Germany), Dr Francesc Figueras (Spain), Professor Stefan Hansson 13 
(Sweden), Professor Kurt Hecher (Germany), Dr Angela Huertas-Ceballos (UK), Dr Mark Lees (Magnus 14 
Life Science, UK), Dr David Ley (Sweden), Professor Neil Marlow (UK), Professor Karel Marsal (Sweden), 15 
Professor John Martin (UK), Dr Eva Morsing (Sweden), Professor Donald Peebles (UK), Professor Neil 16 
Sebire (UK), Professor Ian Zachary (UK) 17 
Corresponding Author: Dr Rebecca N Spencer 18 
Institute for Women’s Health, UCL, 86-96 Chenies Mews, London, WC1E 6HX 19 
Tel: +44 (0)7793 355 359, Fax: +44 (0)207383 7429, email: rebecca.spencer@ucl.ac.uk 20 
Funding sources: This research was funded by the European Commission Seventh Framework 21 
Programme (FP7) and supported by researchers at the National Institute for Health Research (NIHR)  22 
University College London Hospitals Biomedical Research Centre (ALD, DMP). 23 
 Ethics of gene therapy, Version 1.0, 14/12/2015  Page 2 
 
Conflict of Interest: ALD and DMP are consultants for Magnus Growth, for which they receive a token 24 
consultancy payment and shareholding in the company. ALD is director of Magnus Growth, part of 25 
Magnus Life Science, which is aiming to take to market a novel treatment for fetal growth restriction. IZ 26 
is a consultant for Magnus Life, part of Magnus Life Science for which he receives a token consultancy 27 
payment and shareholding in the company. 28 
Key Words: Ethics, fetal growth restriction, gene therapy, translational medicine, pregnancy, qualitative, 29 
interview study 30 
Referee Nominations: Nick Watson, Bobbie Farsides (Brighton-Sussex Medical School), Jan Deprest (KU 31 
Leuven) 32 
  33 
 Ethics of gene therapy, Version 1.0, 14/12/2015  Page 3 
 
Abstract 34 
Objectives: To evaluate the ethical and social acceptability of a proposed clinical trial using maternal 35 
uterine artery vascular endothelial growth factor (VEGF) gene therapy to treat severe early onset fetal 36 
growth restriction (FGR) in pregnant women. 37 
Methods: We conducted a literature review on the ethics and legality of experimental treatments in 38 
pregnant women and in particular of advanced therapeutics. Issues which were identified informed the 39 
interview guides for semi-structured, qualitative interviews, which were carried out in four European 40 
countries with key stakeholders (disability groups, professional bodies, and patient support groups, 41 
n=34) and with women/couples who have experienced pregnancies affected by severe early onset FGR 42 
(n=24). 43 
Results: The literature review identified two main questions; is it ethical to give a pregnant woman a 44 
potentially risky treatment from which she does not directly benefit, and is it ethical to treat this 45 
condition of the unborn child, who may then be born with a serious disability when, without treatment, 46 
they would have died? The review concluded that there was no ethical or legal objection to the 47 
intervention, or to a trial of this intervention. Overall, respondents viewed the proposed trial in positive 48 
terms. Women were generally interested in participating in clinical trials where these conferred a 49 
potential benefit to their unborn child.  The risk of disability for the premature child was a concern, but 50 
not considered a major stumbling block for maternal VEGF gene therapy. 51 
Conclusions: Maternal gene therapy to treat severe early onset FGR appears to be ethically and socially 52 
acceptable. 53 
  54 
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Introduction 55 
Fetal growth restriction (FGR) is a serious obstetric condition, in which defects in placental development 56 
and function result in chronic fetal hypoxia and under-nutrition, and thus a failure of the fetus to reach 57 
its growth potential.
1
  There is currently no treatment for FGR; management involves regular monitoring 58 
of the mother and fetus, often culminating in the need for iatrogenic preterm delivery.
2
 When severe 59 
FGR is detected relatively early in pregnancy, for example before 28 weeks of gestation, this may lead to 60 
the stark choice between delivering a very small and premature baby or risking stillbirth by prolonging 61 
the pregnancy. 62 
The EVERREST Project is a multinational, multidisciplinary collaboration which aims to carry out a phase 63 
I/IIa trial examining the safety and efficacy of maternal gene therapy as a treatment for severe early 64 
onset FGR.
3
 Preclinical studies have shown that vascular endothelial growth factor (VEGF) gene therapy, 65 
delivered locally via an adenoviral vector into the maternal uterine arteries, increases uterine artery 66 
volume blood flow and vasodilated the uterine arteries of pregnant sheep over days 
4
 and weeks 67 
through increased expression of endothelial Nitric Oxide Synthase and perivascular adventitial 68 
angiogenesis.
5, 6
 In animal models of FGR it has also been shown to safely increase fetal growth velocity.
7
  69 
The EVERREST Clinical Trial would involve administration, via interventional radiology, of a VEGF gene 70 
therapy into the maternal uterine arteries in pregnancies affected by severe FGR between 22 and 26 71 
weeks of gestation. The trial centres will be University College London Hospital in the UK, University 72 
Medical Centre Hamburg-Eppendorf in Germany, Hospital Clinic of Barcelona in Spain, and Lund 73 
University in Sweden. As potentially the first clinical use of gene therapy during pregnancy, it raises 74 
important ethical questions.  75 
Through reviewing the relevant published and regulatory literature and undertaking qualitative semi-76 
structured interviews with key stakeholders and patients, this study aimed to establish whether there 77 
were any fundamental ethical or societal objections to the use of maternal gene therapy. 78 
 79 
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Methods 80 
 Literature Review 81 
A thematic review of the literature was conducted, addressing the ethics of research in pregnant 82 
women, the ethics of gene therapy in pregnancy, the ethical aspects and implications of the maternal-83 
fetal relationship, and ethical issues in neonatal care (RA).{Hutton, 1998 #3227} Searches for peer-84 
reviewed articles on these topics were made in English, using Medline and Google Scholar, Spanish, 85 
Catalan, Finnish, Swedish, German, and French. Searches for relevant reports, regulations, and other 86 
publications were made for European Union Institutions, the Council of Europe, the World Medical 87 
Association, the United Nations Educational, Scientific and Cultural Organization (UNESCO), the 88 
International Committee on Harmonisation (ICH), and federal regulations of the United States of 89 
America, including guidance from the National Institutes of Health (NIH) and Food and Drug 90 
Administration (FDA).  91 
 Stakeholder Interviews 92 
The issues raised by this literature review were used to develop an interview guide for semi-structured 93 
qualitative interviews with key stakeholders. This included a one page summary, to be read by the 94 
respondent, giving background information on severe early onset FGR and outlining the proposed 95 
EVERREST Clinical Trial. A more technical summary was used for medical stakeholders, and three 96 
additional questions relating to clinical trials in pregnancy were included for these participants. 97 
Interviews were designed to last around 30 to 40 minutes. Two pilot interviews were conducted in 98 
English before commencing the study. 99 
Stakeholders from the four partner countries, as well as international stakeholders were identified via 100 
internet searches and expert advice from members of the EVERREST Consortium. Initial purposive 101 
sampling included medical organisations, parental support groups, and disability rights groups. In 102 
response to ongoing data analysis, theoretical sampling of midwifery organisations and additional 103 
disability groups was also undertaken. Responses from midwifery organisations were analysed with 104 
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those from parental support groups, reflecting the self-expressed role of these respondents as providing 105 
support and advocacy for pregnant women.  106 
Interviews in the UK and Germany were performed by one bilingual, native language speaker (MS). 107 
Interviews with Swedish stakeholders were conducted in English by the same interviewer, as all 108 
potential respondents had a good command of English. These interviews were mainly via telephone or 109 
Skype, with some face-to-face interviews with UK participants. Interviews in Spain were conducted by a 110 
Spanish speaking bilingual interviewer (MYA) who was briefed and debriefed in detail by the lead 111 
interviewer (MS). Interviews were recorded and transcribed, either verbatim for interviews in English, or 112 
translated and transcribed into English for interviews in German and Spanish. Transcription and 113 
translation was carried out on an ongoing basis during the study, allowing the refining of some of the 114 
questions and pursuing specific avenues of enquiry in more depth. The interviews were content 115 
analysed on an ongoing basis from the beginning of the research (MS) to improve the collection of 116 
information in subsequent interviews. The data was coded manually, with sections of data labelled with 117 
a summative phrase and then analysed thematically to identify patterns within the data.
8
 118 
 Patient Interviews 119 
The results of the stakeholder interviews, together with the findings of the literature review, were used 120 
to design the interview guide for semi-structured qualitative interviews with patients. Fetal medicine 121 
specialists from London, Hamburg, Barcelona, and Lund identified potential participants whom they had 122 
previously managed for severe early onset FGR. Women and their partners were eligible to participate if 123 
they were between 18 and 65, spoke the native language of the country in which they were recruited, 124 
and had had a pregnancy affected by severe early onset FGR which ended between 3 months and not 125 
more than 5 years before recruitment. The upper age limit was included as part of the application for 126 
proportionate ethics review in the UK. Women were contacted and informed about the study by a 127 
healthcare professional from their original treatment centre. In the UK women were only approached 128 
after approval from their General Practitioner. Written informed consent was given by all participants.  129 
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All patients were interviewed face-to-face by a native language speaker (MS in UK and Germany, AML in 130 
Spain, PL in Sweden), either in the patient’s home or at the original treatment centre, according to the 131 
preference of the respondent. The UK interviewer attended the interviews in Spain and briefed and 132 
debriefed the Swedish interviewer via Skype. Interviews lasted 60 to 90 minutes, with digital recordings 133 
of all interviews stored as encrypted and password protected files. Transcription, translation, and 134 
analysis were performed in the same manner as for the stakeholder interviews. 135 
The patient interview study was sponsored by the University College London Comprehensive Clinical 136 
Trials Unit (UCL CCTU). Ethical approval was provided by the National Research Ethics Service 137 
Committee East of England in the UK, the Hospital Clinic of Barcelona’s Clinical Research Ethics 138 
Committee in Spain, the Regional Ethical Review Board in Lund for Sweden, and the Ethics Committee of 139 
Hamburg Board of Physicians in Germany. Local Research and Development approval was obtained as 140 
required. All respondents had the option of receiving a summary report of the study findings. 141 
 142 
Results 143 
 Literature Review 144 
One fundamental issue raised by the literature review was the ethical status of offering a potentially 145 
risky medical treatment to a pregnant woman which confers no benefit to maternal health, but which 146 
may improve the health and survival prospects of her as yet unborn baby. It is central to medical ethics, 147 
and in most jurisdictions to medical law as well, that the primary patient in pregnancy is the woman 148 
herself, not the fetus. However, the ethical question remains as to whether the woman and the fetus 149 
constitute two patients with equal moral status, two patients with unequal moral status, or one 150 
patient.
9-13
 Here “moral status” refers to the moral value inherent in “personhood”.  Although moral 151 
status is sometimes (especially in neonatology ethics) considered gradually acquired through gestation 152 
and birth, for practical purposes in reproductive ethics it is usually considered a categorical concept: one 153 
either has it or does not have it. 154 
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The simplest analysis considers that there is only one patient: the woman herself. Regardless of whether 155 
or not the fetus ‘matters’ from a moral standpoint, only the woman has the full moral status that goes 156 
with moral agency – the ability to make decisions, the capacity to value actions and states of affairs, and 157 
the right to respect for one’s autonomy. In light of respect for autonomy, we can say that while we 158 
cannot oblige or compel a woman to undergo medical treatment for the sake of her fetus alone, any 159 
more than we can oblige or compel a woman to undergo medical treatment for her own sake, we can 160 
also respect a woman’s choice to act (or refrain from acting) in the interests of her developing fetus. 161 
Thus, should she choose to risk her own health, or undergo treatment which will benefit her fetus but 162 
not (necessarily) herself directly, this is a choice which should be respected and may be acted upon.  163 
Many obstetricians, and some others, consider that in care of the pregnant woman they are looking 164 
after two patients, the woman and her unborn child. A weak version of this thesis is that there are two 165 
patients, but that if the interests of the two conflict, the interests of the adult woman take priority. A 166 
strong version of this thesis is that no such tie-break applies: both sets of interests are of equal strength 167 
and importance. On the two patient model, it is clearer that there will be obligations to do whatever can 168 
feasibly be done to promote fetal development, with a view to the long term interests of the child-to-169 
be, so long as these are consistent with the interests of the mother. Such treatment, however, could not 170 
legally be imposed on a competent woman without her consent.  171 
Given that, for both the one patient and two patient models, treatment which provides a direct benefit 172 
solely to the fetus is permissible but not obligatory, the issue becomes the ethical status of a trial of 173 
maternal gene therapy. The international ethical standard for clinical trials is the World Medical 174 
Association’s Declaration of Helsinki.
14
 This relies on three central ethical requirements: the 175 
responsibility of the physician (as a matter of general medical ethics) for the well-being and safety of his 176 
or her patients; the centrality of informed consent; and the need for research to offer a fair and 177 
proportionate balance of risk and benefit to all participants. It makes no reference to the inclusion (or 178 
exclusion) of women – pregnant or otherwise – in particular in research or to gene therapy.  The key test 179 
for the ethical acceptability of research which is not therapeutic is that it should pose no more than 180 
minimal additional risk to the participants, over and above the risk of procedures they are ordinarily 181 
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undergoing in their clinical care.  If this is satisfied, then the next crucial test is consent. In the EVERREST 182 
trial the key concern was the consent to a procedure which is for research, offers no guarantee of 183 
benefit, and in a context of fetal growth restriction could be psychologically burdensome and 184 
unacceptable. The interviews in the study were designed to explore this question in more detail. 185 
 Semi-structured Interviews 186 
Fifty five stakeholder organisations were contacted, of which 34 agreed to participate (Table 1). The 187 
remainder either declined to be interviewed or referred the request to another organisation (Table 2). 188 
There was considerable difficulty recruiting Spanish stakeholders; the two organisations which did 189 
participate would only agree to be interviewed in writing via email, with telephone follow-up to verify 190 
unclear answers, conducted in native Spanish (supervised by MS). Two German organisations, one 191 
medical and one parental, felt that a trial of gene therapy in pregnancy would be unethical. 192 
Unfortunately neither was willing to discuss their beliefs in more detail.  193 
Twenty one interviews were carried out with women who had had pregnancies previously affected by 194 
severe early onset FGR (UK=7, Germany=7, Sweden=3, Spain=4). Five of these women had experienced a 195 
mid-trimester miscarriage or stillbirth and two of them had chosen to terminate an affected pregnancy. 196 
19 women had undergone at least one preterm delivery for FGR, between 24 and 32 weeks' gestation, 197 
and two of these liveborn babies had subsequently died. In Spain there were a further three interviews 198 
with partners of women who had had affected pregnancies. In one case this was because the woman 199 
spoke limited Spanish, and in the other two because the husband attended the interview alone. It was 200 
not felt to be appropriate to turn these respondents away after they had made the effort to attend the 201 
interview, nor to remove their responses from the study. In Sweden there was difficulty in recruiting 202 
women as research had been conducted before in this same group of patients, and many were reluctant 203 
to take part in a further study.  204 
On the question of the moral status of the fetus, stakeholders expressed divergent views when asked 205 
whom they would consider a patient in the context of a therapy for FGR. While the majority held that 206 
the pregnant woman was the patient, several stakeholders viewed both the woman and the fetus as 207 
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patients, while some saw the fetus as the patient, because it was the fetus that required treatment. A 208 
majority of the women across all four countries considered the fetus to be a person, although there was 209 
some divergence as to what time point in pregnancy this began. When asked whose interests should 210 
take priority, just over half of the women considered the interests of the unborn child as more 211 
important than their own. A few thought that the interests of the woman and the child were of equal 212 
importance and a few considered the interests of the pregnant woman to be more important than those 213 
of the child. This was particularly the case where the woman already had other children or where the 214 
fetus was not at a gestational age or weight where it was likely to survive outside of the womb.  215 
On the issue of maternal treatment for fetal benefit, all of the women and all but one of the 216 
stakeholders felt that this was acceptable, providing the woman was in agreement and there were no 217 
major risks involved, or that she understood the risks to herself and the fetus. Medical stakeholders 218 
stressed that many current treatments already fell into this category, and both parental and medical 219 
stakeholders cited the possibility of fetal benefit being of indirect benefit to the woman.  220 
“One does a caesarean section in mothers because one wants to save the fetus but the 221 
caesarean section is of no benefit to the mother… All of fetal therapy, in particular fetal 222 
surgery, is basically clearly dangerous for the mother and is only done because it is of 223 
benefit to the child.” Medical stakeholder, Germany 224 
Only a few of the patients had experience of being asked to participate in a clinical trial during 225 
pregnancy. However, the vast majority of women could imagine taking part in such a trial as long as they 226 
were given sufficient information. Reasons advanced for participation included an attempt to improve 227 
the critical situation for their unborn child and helping other women in their situation in the future. For 228 
the majority of women the main concern about participating in a clinical trial was the potential for harm 229 
to the fetus. Only a few respondents expressed any concern about potential serious risk to themselves, 230 
particularly if this would mean that they might not be able to look after their baby. In this light, all 231 
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respondents suggested that they would be more inclined to participate in a clinical trial if the treatment 232 
investigated was likely to confer a benefit to their unborn child rather than to themselves. 233 
“It is my child. My love would be much too great to think of myself. I think it is more 234 
important to give something to the child in the last analysis. I already have lived my life so 235 
far. And she has not done that so far.” Patient, Germany 236 
In relation to the proposed EVERREST Clinical Trial, the majority of stakeholders, and in particular non-237 
medical stakeholders, were concerned about the psychological burden that making a decision to take 238 
part, or taking part, may place on women at an already very stressful time. It was suggested that a 239 
woman may be uncertain and anxious that, whatever her decision, the outcome would be somehow her 240 
fault. Most stakeholders still felt that women would be able to make an autonomous decision in these 241 
circumstances, and would not feel obliged to participate. However, some stakeholders expressed 242 
concern that the psychological state of a woman experiencing a pregnancy affected by severe early 243 
onset FGR might not be conducive to making a rational decision. A few stakeholders questioned the 244 
decision-making capacity of pregnant women in general, suggesting that a pregnant woman would 245 
always wish to do the best for her child even if that acted against her own needs. 246 
The majority of interviewed patients felt that they had been capable of making decisions regarding 247 
management options at the time of the diagnosis of severe early-onset FGR. Most women stated that 248 
they arrived at a decision themselves about their pregnancy, although they had discussed the options 249 
with their partners and listened to the advice of healthcare professionals. A majority of women 250 
acknowledged that it might be difficult to think clearly and rationally when faced with a decision 251 
regarding a new experimental treatment at the time when their unborn child had just been diagnosed 252 
with severe early onset FGR. However, this did not appear to be an insurmountable problem as long as 253 
they had some time to consider, and someone with whom to discuss the intervention. All of the 254 
respondents thought that they would have been able to arrive at the decision freely and did not feel 255 
that they would be pressured to participate by healthcare professionals, although a few thought they 256 
might put themselves under emotional pressure. 257 
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“So in between this horrific experience you can have time when you are thinking clearly. I 258 
don’t think you are necessarily out of control the whole time. I’m not.” Patient, UK  259 
“The pressure is not from the medics… but from oneself. That one fears that if one does not 260 
participate then the baby will stay small. I would then be without hope.”                            261 
Patient, Germany 262 
A frequent concern among non-medical stakeholders was that it would be difficult to obtain valid 263 
informed consent for participation in the EVERREST Clinical Trial, as it would be difficult for lay people to 264 
understand the intervention and its possible outcomes. Added to this was the limited public 265 
understanding of gene therapy and prejudice against it. In contrast, medical stakeholders were not 266 
concerned, as they felt that obtaining informed consent would be no different from many other trials. 267 
Stakeholders agreed that trial participants should be given independent advice, for example from 268 
psychologists, midwives, or parental organisations. They highlighted the need for informed consent to 269 
be a continuing process rather than a single event, and for women to be given time to consider whether 270 
or not to participate in the trial. The woman or couple would need printed, clearly written information 271 
to take away, so that they could discuss participation without any pressure being exerted by the 272 
healthcare team. 273 
 “I think the most important thing in this trial as with all trials is that one explains it at the 274 
level of the patient and not at an academic level … one needs to use simple vocabulary and 275 
one needs to keep on repeating it because these parents … are in a certain state of shock” 276 
International parental organisation 277 
Information, support, and time were also raised by the patients as important factors when deciding 278 
whether or not to participate in a clinical trial. The need for accurate and adequate information was 279 
mentioned by all the patients, and most preferred this to be given by the treating doctor rather than a 280 
doctor involved in the trial. Almost all respondents would involve their partners in the decision 281 
regarding trial participation, although the final decision would be the woman’s. They would also want to 282 
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speak with someone who was independent of the trial, including other pregnant women who had 283 
experienced a similar situation.  284 
Almost all patients spontaneously expressed a positive reaction to the proposed EVERREST Clinical Trial, 285 
with some stating that they wished it had been available at the time of their pregnancy. A minority of 286 
patients had a negative response, suggesting that the trial was intervening in nature, that any first-in-287 
human trial may be risky, and that it may have harmful consequences for participating women. When 288 
patients who were initially positive were probed about any potential problems with the trial, the main 289 
concerns, expressed by a minority, were that the treatment may be ineffective or may cross the 290 
placenta, potentially resulting in unknown effects on the fetus. Some women were also concerned that 291 
it may have harmful long term consequences for the woman and/or child or that the administration 292 
procedure might be risky. 293 
“I think you would need to be hopeful, but you would also need to be realistic that it might 294 
not work. But that hope might be that it’s what you’re looking for, I suppose. If it didn’t 295 
work, I think my husband would worry about how I would pick myself up from that again, 296 
having gone through what I’ve gone through…” Patient, UK 297 
“It's not the treatment what worries me, but the potential consequences that it could have 298 
for the baby. In this case I would not be worried about me at all… it’s not knowing how it 299 
could affect the baby.” Patient, Spain 300 
Two potential issues raised by the literature review were that the trial may either be seen as 301 
discriminating against people with disabilities, or in contrast may result in the birth of babies with 302 
severe disabilities who would otherwise have died in utero. Most stakeholders, including disability 303 
rights groups, did not consider the proposed trial would be discriminatory, as the primary aim was 304 
not to eliminate disability. A minority of stakeholders felt that some people within the disability 305 
movement might be concerned about the trial intervention, particularly because of the use of the 306 
term ‘gene therapy’. 307 
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“I can’t see from a disability perspective anyway that there’s any problem with this at all… 308 
because it’s not, you know, like a search and destroy operation which I think, you know, the 309 
Downs syndrome tests are.” UK disability movement stakeholder 310 
Over half of the patients were very clear that it was acceptable to them to have a disabled child, as long 311 
as the disability was not caused by the trial intervention itself. Several respondents stressed that it was 312 
preferable to have a disabled child rather than a dead child. A minority of the patients, would not find it 313 
acceptable to have a disabled child who would have died without the trial, as they felt that the disability 314 
would harm not only the life of the child but also affect the lives of their other children. One respondent 315 
expressed the concern that the trial might lead to societal and economic problems if the net effect was 316 
to produce many more severely disabled children. 317 
“I think it is still better to have a disabled child than a dead child…because in the last 318 
analysis I had decided to have a child. My [child] could have been born with a disability. I 319 
decided to have [him or her] and I will stick with that. And therefore rather this way than not 320 
to have [him or her] at all.” Patient, Germany 321 
The majority of stakeholders and patients were not concerned by the novelty of maternal gene therapy. 322 
The main exception was a German stakeholder who felt that the negative societal view of gene therapy 323 
in Germany would make the intervention unacceptable. Interestingly, this view was not shared by the 324 
German patients. Several stakeholders highlighted the importance of communicating to the public what 325 
maternal gene therapy would entail, while some patients suggested it would be preferable to avoid the 326 
term ‘gene therapy’ to eliminate any misunderstanding regarding the purpose of the treatment. 327 
“The term gene therapy causes fear because one thinks that it causes genetic changes to the 328 
baby …Because the term gene therapy is used one thinks as a lay person that …maybe one 329 
should use a different term...” Patient, Germany 330 
All but one of the patients were in favour of the trial taking place, and the great majority would have 331 
wanted to participate in such a trial. The patients who would have declined participation cited concerns 332 
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about the unknown risks of the intervention or the possibility of a child surviving with severe disability. 333 
Stakeholders also had a generally favourable view of the ethics and social acceptability of the trial. They 334 
mostly felt the ethical issues were those raised by any clinical trial in pregnancy, including the 335 
psychological burden on women and the challenges of obtaining informed consent. Assuming the 336 
intervention was effective, the main concern for stakeholders was the risk of harm. 337 
 “[I would be in favour] on the condition that long term data is shown about safety and on 338 
the condition that experts who are completely independent, i.e. who have no reason to be in 339 
favour of this trial starting, will say that they consider it safe, that they consider it 340 
acceptable to treat the fetus via the mother.” Medical stakeholder, Germany 341 
 “I would have wanted to participate in the trial even if one would not know whether it 342 
would work or not.” Patient, Sweden  343 
“There has to come a time when the intervention is trialled and, and that obviously, has its 344 
challenges, its sensitivities etc. But if it’s handled carefully and ultimately we have an 345 
improvement in outcome for these very high-risk pregnancies, then, for us as an 346 
organisation, that’s a positive outcome.” Parental organisation, UK 347 
 348 
Discussion 349 
The findings of this study indicate that a trial of maternal gene therapy to treat severe early-onset FGR is 350 
ethically acceptable to many key stakeholders and women who have had previously affected 351 
pregnancies. While participants expressed varying views on the personhood of the fetus, the concept of 352 
a maternal intervention for fetal benefit was acceptable to all but one of the interviewees. In relation to 353 
the proposed trial of maternal VEGF gene therapy, information, independent advice, and sufficient time 354 
for decision making were highlighted as important issues by patients and stakeholders. Although the 355 
psychological burden of trial participation was a concern for stakeholders, most interviewees felt that 356 
pregnant women would be capable of making an autonomous decision about whether or not to take 357 
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part. Almost all patients viewed the proposed trial positively, and most felt that they would have 358 
wanted to participate. 359 
The aim of this study was to identify any fundamental or insurmountable ethical objections to a trial of 360 
maternal gene therapy for severe early onset FGR. It did not aim to either quantify the distribution, or 361 
provide an in-depth characterisation, of societal attitudes towards the proposed trial. Purposive and 362 
theoretical sampling was used to try to identify a diversity of opinion, not to provide a statistically 363 
representative sample. Similarly a thematic analysis, conducted in light of the narrative literature 364 
review, aimed to identify discordant and outlier views, rather than develop an overarching conceptual 365 
model. Triangulation of the findings from the literature review, stakeholder interviews, and interviews 366 
with patients demonstrated consistency of opinion, supporting the credibility of the results. 367 
Independent, internal peer review of the results was provided by the EVERREST Independent Ethics 368 
Advisory Board
3
 comprising experts in ethics and law, philosophy, social sciences and disability rights.  369 
One important limitation of this study is that the attitudes and beliefs of women with previously 370 
affected pregnancies may not have been the same at the time of interview as they were at the time of 371 
diagnosis. We judged that it would not be appropriate to undertake interviews with women currently 372 
experiencing an affected pregnancy, as it raised the possibility of an intervention when no current 373 
treatment is available. It should also be noted that the majority of stakeholders were from Northern 374 
Europe, especially the UK, and this may have affected the range of views expressed. This was partly 375 
because of the greater number of parental support and disability rights groups in the UK, many of which 376 
are organised on a professional basis. This is in contrast to the organisations in many other European 377 
countries, which generally receive less funding, and are often staffed by unpaid volunteers. 378 
While the views of the stakeholder groups were broadly positive, two exceptions should be noted: one 379 
was that some German stakeholders felt strongly that a gene therapy trial of this kind would be 380 
unacceptable because of the history of eugenics in the Nazi period.  It is not clear how widely held this 381 
view would be; or what the connection is between the eugenic practices referred to and the trial here 382 
with its goal of supporting and promoting fetal survival and welfare. The other view was shared by some 383 
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midwives, who felt that this trial was part of a tendency to “overmedicalise” pregnancy. We had no 384 
evidence that this view was shared by any of the women interviewees.  The views expressed by the 385 
women in our study echo the findings of other qualitative studies exploring women’s experiences of 386 
obstetric research. Four studies carried out interviews with women who participated in ORACLE 
15
 387 
(randomised controlled trial [RCT] of antibiotics in preterm labour) and Magpie 
16
 (RCT of prophylactic 388 
magnesium sulphate for severe pre-eclampsia), and women who were approached to participate in 389 
PLUTO 
17
 (RCT of percutaneous shunting in fetal lower urinary tract obstruction) and eight other clinical 390 
obstetric trials 
18
. They found that key reasons for participation were the possibility of benefit for the 391 
woman or fetus and altruism - potential motivations suggested by women in our study. As anticipated 392 
by our interviewees, women who took part in these trials described feeling free to make their own 393 
decision about participation, with varying degrees of input from their partners 
15, 16, 18
. However, they 394 
also described limitations in the consent procedures, including a lack of information and explanation 
16, 395 
17
 and a lack of time for discussion with research staff 
18
. As suggested by patients in our study, women 396 
who considered participation in PLUTO said it would have been useful to speak to someone with 397 
personal experience of their clinical situation 
17
. Only one other study has investigated women’s 398 
attitudes to a potential clinical trial. The strong opposition that women voiced to the idea of an RCT of 399 
Caesarean section versus vaginal delivery in first time mothers 
19
 is in stark contrast to the generally 400 
positive reaction of patients towards the proposed EVERREST trial.  401 
It is clear from the review of the regulatory literature, the opinions expressed by our interviewees, and 402 
the reported experiences of women who have participated in other obstetric trials, that obtaining valid 403 
informed consent will be a key issue for a trial of maternal gene therapy. As well as providing sufficient 404 
information and time, it will be important to bear in mind and strive to minimise the psychological 405 
burden for potential participants. However, the women interviewed in this study also felt that they 406 
would have been capable of reaching an autonomous decision, even at a very difficult time, and most 407 
would have wanted the option of participating in the proposed EVERREST clinical trial. 408 
 409 
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Table 1: Key stakeholders interviewed about the ethics and social acceptability of the proposed EVERREST Clinical Trial by country and type of stakeholder 477 
 
Nationality 
Type of stakeholder  
Total Medical Parental and Midwifery Disability 
International 1. European Critical Care Foundation 
(ECCF) 
2. International Stillbirth Alliance (ISA) 
3. European Society of Paediatric 
Neonatal Intensive Care (ESPNIC) 
1. European Foundation for the Care of Newborn 
Infants (EFCNI) 
1. International Federation for Spina 
Bifida and Hydrocephalus (IF Global) 
5 
UK 1. British Association of Perinatal 
Medicine (BAPM) 
2. Royal College of Obstetricians and 
Gynaecologists (RCOG) 
3. British Maternal and Fetal Medicine 
Society (BMFMS) 
1. Antenatal Results and Choices (ARC) 
2. BLISS charity, for babies born too soon, too 
small, too sick 
3. Child Growth Foundation 
4. Stillbirth and Neonatal Death charity (SANDS) 
5. Tommy’s charity 
6. Royal College of Midwives (RCM) 
1. Liberation Network Alliance 
2. Alliance for Inclusive Education 
3. Inclusion London 
4. Disability Rights UK 
5. Disability Rights Commission 
6. British Council of Disabled People 
(BCODP) 
7. Bristol Disability Forum 
8. Scope charity 
17 
Germany 1. Deutsche Gesellschaft für Perinatale 
Medizin 
2. Deutsche Gesellschaft für 
Neonatologie 
1. Bundesverband "Das frühgeborene Kind" e.V. 
2. Frühstart München 
3. Deutscher Hebammenverband (German 
Association of Midwives) 
 5 
Sweden 1. Swedish Society of Obstetrics and 
Gynaecology 
2. Swedish Society for Neonatology 
1. Riksförbundet Svenska Prematurförbundet 
2. Prematurföreningen Mirakel 
3. Swedish Association of Midwives 
 5 
Spain 1. Spanish Society of Obstetricians and 
Gynaecologists 
1. Asociación Valenciana de Padres de Niños 
(AVAPREM) 
 2 
Total 11 14 9 34 
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Table 2: Distribution of non-respondents for stakeholder interviews, by country and type of 478 




Type of stakeholder  
Total Medical Parental and Midwifery Disability 
International 3/6 0/1 2/3 5/10 
UK 0/3 2/8 6/14 8/25 
Germany 1/3 1/4 2/2 4/9 
Sweden 0/2 1/4 0/0 1/6 
Spain 1/2 2/3 0/0 3/5 
Total 5/16 6/20 10/19 21/55 
 481 
